Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 131 Gastrointestinal Stromal Tumors 67 Leukemia 66 Leukemia, Myeloid, Chronic-Phase 47 Precursor Cell Lymphoblastic Leukemia-Lymphoma 41 Blast Crisis 22 Brain Neoplasms 15 Philadelphia Chromosome 14 Melanoma 13 Sarcoma 12 Neoplasms 12 Neoplasm Metastasis 12 Leukemia, Myeloid, Acute 12 Leukemia, Myeloid, Accelerated Phase 12 Glioblastoma 12 Lung Neoplasms 11 Prostatic Neoplasms 10 Leukemia, Myeloid 9 Gliosarcoma 9 Glioma 8 Breast Neoplasms 8 Primary Myelofibrosis 7 Leukemia, Myelomonocytic, Chronic 7 Central Nervous System Neoplasms 7 Astrocytoma 7 Recurrence 6 Polycythemia Vera 6 Ovarian Neoplasms 6 Oligodendroglioma 6 Myeloproliferative Disorders 6

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × Imatinib Mesylate × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡